Compare Air Products & Chemicals, Inc. (APD) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Air Products & Chemicals, Inc. vs 10X Genomics Inc — how do they compare? Air Products & Chemicals, Inc. trades at $308.56 (market cap $68.63B), while 10X Genomics Inc trades at $58.6 (market cap $7.64B). The key difference: Air Products & Chemicals, Inc. is far larger — about 9× 10X Genomics Inc's market cap, and Air Products & Chemicals, Inc. pays a 2.35% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| APD | TXG | |
|---|---|---|
Market Cap | $68.63B | $7.64B |
Sector | Basic Materials | Health |
52-Week High | $314.19 | $58.57 |
52-Week Low | $230.42 | $11.34 |
Enterprise Value | $85.80B | $7.17B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Air Products and Chemicals (APD) trades at $303.44, up 1.17% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The stock shows strong analyst support with a consensus price target of $346, though high valuation ratios like a P/E of 30.86 and EV/EBITDA of 50.36 raise concerns. Recent news highlights a major semiconductor supply deal in Taiwan and raised guidance after Q3 2026 results.
The outlook is mixed: positive momentum from contract wins and earnings performance offers upside, but negative net income margins and elevated debt levels pose risks. Investors should weigh growth catalysts against financial leverage and profitability challenges.
TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.
The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
